Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.

J Hepatol

Department of Epidemiology, School of Public Health (Guangdong Provincial Key Laboratory of Tropical Disease Research), Southern Medical University, Guangzhou, China. Electronic address:

Published: August 2024

AI Article Synopsis

  • Frailty significantly increases the risk of developing chronic liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and liver cancer, as well as liver-related mortality.
  • A comprehensive study involving over 339,000 participants found that those classified as prefrail or frail had substantially higher risks for these conditions compared to non-frail individuals, based on a follow-up period averaging 11.6 years.
  • The findings suggest a need for public health initiatives aimed at reducing the risk of liver diseases in frail populations, emphasizing the importance of addressing frailty in chronic disease management.

Article Abstract

Background & Aims: Frailty is associated with multiple morbidities. However, its effect on chronic liver diseases remains largely unexplored. This study evaluated the association of frailty with the risk of incident metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, liver cancer, and liver-related mortality.

Methods: A total of 339,298 participants without prior liver diseases from the UK Biobank were included. Baseline frailty was assessed by physical frailty and the frailty index, categorizing participants as non-frail, prefrail, or frail. The primary outcome was MASLD, with secondary outcomes, including cirrhosis, liver cancer, and liver-related mortality, confirmed through hospital admission records and death registries.

Results: During a median follow-up of 11.6 years, 4,667 MASLD, 1,636 cirrhosis, 257 liver cancer, and 646 liver-related mortality cases were identified. After multivariable adjustment, the risk of MASLD was found to be higher in participants with prefrailty (physical frailty: hazard ratio [HR] 1.66, 95% CI 1.40-1.97; frailty index: HR 2.01, 95% CI 1.67-2.42) and frailty (physical frailty: HR 3.32, 95% CI 2.54-4.34; frailty index: HR 4.54, 95% CI 3.65-5.66) than in those with non-frailty. Similar results were also observed for cirrhosis, liver cancer, and liver-related mortality. Additionally, the frail groups had a higher risk of MASLD, which was defined as MRI-derived liver proton density fat fraction >5%, than the non-frail group (physical frailty: odds ratio 1.64, 95% CI 1.32-2.04; frailty index: odds ratio 1.48, 95% CI 1.30-1.68).

Conclusions: Frailty was associated with an increased risk of chronic liver diseases. Public health strategies should target reducing chronic liver disease risk in frail individuals.

Impact And Implications: While frailty is common and associated with a poor prognosis in people with MASLD (metabolic dysfunction-associated steatotic liver disease) and advanced chronic liver diseases, its impact on the subsequent risk of these outcomes remains largely unexplored. Our study showed that frailty was associated with increased risks of MASLD, cirrhosis, liver cancer, and liver-related mortality. This finding suggests that assessing frailty may help identify a high-risk population vulnerable to developing chronic liver diseases. Implementing strategies that target frailty could have major public health benefits for liver-related disease prevention.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2024.08.024DOI Listing

Publication Analysis

Top Keywords

chronic liver
24
liver diseases
24
liver cancer
20
frailty
18
liver
16
liver disease
16
cirrhosis liver
16
cancer liver-related
16
physical frailty
16
liver-related mortality
16

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!